Drug Profile
Tasonermin - Genentech/Boehringer Ingelheim
Alternative Names: Beromun; FK 516; TNF alpha - Genentech/Boehringer Ingelheim; TNF alpha-1a - Genentech/Boehringer Ingelheim; Tumour necrosis factor alpha - Genentech/Boehringer IngelheimLatest Information Update: 24 Oct 2021
Price :
$50
*
At a glance
- Originator Genentech
- Developer Amarillo Biosciences; Asahi Kasei; Genentech; Hayashibara
- Class Antineoplastics; Blood proteins; Glycoproteins; Monokines; Tumour necrosis factors
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Sarcoma
- Preregistration Submission Withdrawal Cancer
Most Recent Events
- 11 Jun 2015 Launched for Sarcoma in Latvia, Lithuania, Luxembourg, Slovakia, Croatia, Estonia, Austria, Finland, France, Hungary, Malta, Romania and Slovenia (IV) before June 2015
- 04 Oct 2001 A preclinical study has been added to the Cancer pharmacodynamics section
- 20 Jan 2000 Mochida has withdrawn the NDA for TNFα in Japan